Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
Status:
Recruiting
Trial end date:
2022-12-25
Target enrollment:
Participant gender:
Summary
This project aims to evaluate the potential rapid and sustained antisuicidal and
antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood
episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid
recent abuse of alcohol.
Phase:
Phase 3
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston